Title:
ＣＤ７３を標的とする抗体および抗体－薬物複合体、その製造方法と使用
Document Type and Number:
Japanese Patent JP7330996
Kind Code:
B2
Abstract:
Disclosed by the present invention are a targeted CD73 antibody and an antibody-drug conjugate (ADC), and a preparation method therefor and application thereof. Further disclosed is a method for preparing the described monoclonal antibody and ADC. The monoclonal antibody and the corresponding ADC disclosed by the present invention can be efficiently and highly specifically combined with purified CD73 protein and CD73 on the surfaces of multiple tumor cells to block the catalytic activity of CD73 enzyme, and have high affinity, low immunogenicity and significant anti-tumor effect.
Inventors:
You, ke
Jin, Louis
Liu, Lian
Jin, Louis
Liu, Lian
Application Number:
JP2020546414A
Publication Date:
August 22, 2023
Filing Date:
March 07, 2019
Export Citation:
Assignee:
FUDAN UNIVERSITY
Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
International Classes:
C07K16/30; A61K31/407; A61K31/5517; A61K35/12; A61K39/395; A61K47/55; A61K47/68; A61P35/00; A61P35/04; A61P43/00; C07K16/46; C07K19/00; C12N5/10; C12N15/13
Domestic Patent References:
| JP2017537620A |
Foreign References:
| WO2017149515A1 |
Attorney, Agent or Firm:
Kiyoshi Kuzuwa
Previous Patent: Glass-ceramic plate for fireplace insert and method for its production
Next Patent: MOLDING MADE FROM POLYSTYRENE RESIN COMPOSITION
Next Patent: MOLDING MADE FROM POLYSTYRENE RESIN COMPOSITION